Research Article
Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF
Table 2
Overall rate of anti-VEGF treatment.
| | Anti-VEGF treatment | Anti-VEGF IVI count | Time to 6 injections (days) | Time to all injections (days) | Injection rate—first 6 (days per injection) | Injection rate—all (days per injection) |
| | All | 11.1 ± 4.7 (9) | 466.9 ± 270.3 (376) | 913.0 ± 454.1 (854) | 77.8 ± 45.0 (62.7) | 83.9 ± 35.4 (76.5) | | First 6 IVI—EYLEA, N = 10 | 7.7 ± 1.3 (8) | 328.4 ± 110.0 (302.5) | 418.8 ± 155.3 (445.5) | 54.7 ± 18.3 (50.4) | 53.8 ± 17.4 (56.0) | | First 6 IVI—Lucentis, N = 35 | 12.2 ± 5.2 (11) | 480.5 ± 260.8 (451.0) | 1094.0 ± 335.5 (1213.0) | 80.1 ± 43.5 (75.2) | 97.6 ± 34.6 (91.4) | | First 6 IVI—mixed, N = 33 | 10.8 ± 4.2 (9) | 498.0 ± 307.8 (373.0) | 860.2 ± 507.3 (763.0) | 83.0 ± 51.3 (62.2) | 78.4 ± 34.4 (72.7) |
|
|
Data are presented as mean ± SD with the median shown in parenthesis.
|
